Decheng Capital LLC holds a concentrated book of 14 stocks worth $731.7M as of Q2 2026 (disclosed Aug 14, 2026, a ~45-day 13F lag). This quarter they opened Tango Therapeutics Inc and trimmed Arcus Biosciences Inc. Their largest long position is CG Oncology Inc at 62% of the equity book.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
99% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Decheng Capital LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| BlackRock, Inc. | 14 / 14 | $3.2B |
| STATE STREET CORP | 14 / 14 | $2.1B |
| GEODE CAPITAL MANAGEMENT, LLC | 14 / 14 | $1.4B |
| UBS Group AG | 14 / 14 | $608.9M |
| MORGAN STANLEY | 14 / 14 | $254.9M |
| NORTHERN TRUST CORP | 14 / 14 | $245.1M |
| Tower Research Capital LLC (TRC) | 14 / 14 | $2.3M |
| FMR LLC | 13 / 14 | $3.0B |
Ranked by how many of Decheng Capital LLC's top 14 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | CG Oncology Inc COM | $452.7M | 6.37M | 61.9% | —Held | |
| 2 | Nuvation Bio Inc. COM | $147.4M | 25.95M | 20.1% | —Held | |
| 3 | Aardvark Therapeutics Inc COM | $22.6M | 3.92M | 3.1% | —Held | |
| 4 | Aclaris Therapeutics, Inc. COM | $21.4M | 4.04M | 2.9% | —Held | |
| 5 | Upstream Bio Inc. COM | $18.9M | 2.72M | 2.6% | —Held | |
| 6 | Arcus Biosciences, Inc COM | $14.3M | 464.8K | 2.0% | ▼−2.7% Reduced · −13K sh | |
| 7 | Equillium Inc. COM | $14.2M | 4.45M | 1.9% | —Held | |
| 8 | Revolution Medicines Inc(nsm) COM | $9.9M | 52.7K | 1.3% | ▼−44% Reduced · −41K sh | |
| 9 | Lyell Immunopharma, Inc. COM | $9.7M | 692.0K | 1.3% | —Held | |
| 10 | BeyondSpring Inc. SHS | $6.7M | 3.80M | 0.9% | —Held | |
| 11 | Zentalis Pharmaceuticals Inc. COM | $6.4M | 1.32M | 0.9% | —Held | |
| 12 | Newamsterdam Pharma Co NV COM | $6.0M | 176.9K | 0.8% | ▼−46% Reduced · −148K sh | |
| 13 | Pyxis Oncology, Inc (formerly Apexigen) COM | $984K | 326.8K | 0.1% | —Held | |
| 14 | Tango Therapeutics Inc COM | $625K | 20.0K | 0.1% | ▲New New position |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2010850/holdings"
Use Arkolith to show Decheng Capital LLC's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.